KRAS and cancer: With the general recognition of oncogene- over histology-driven tumor vulnerabilities in the early 2000s, pan-cancer sequencing efforts revealed a tissue-context-dependent distribution of mutational subtypes, with KRAS(G12C) being the most frequent mutation in NSCLC (45% of all RAS mutations), followed by KRAS(G12V) (~20%) and KRAS(G12D) (~10%) [23,27].